Lablabo creates pack for HRT treatment

Published: 24-Jan-2011
Drug Delivery Pharmaceutical

Uses an airless metering dispenser with EasyFoil aluminium pouch

Lablabo of France has developed a high-performance airless pack for Azur Pharma’s Elestrin hormonal replacement therapy, which has been launched in the US following approval by the US Food and Drug Administration.

Lablabo’s pack consists of a Sillage airless metering dispenser with an EasyFoil aluminium pouch.

Made of an aluminium and polyethylen multilayer foil, this new pouch is said to ensure maximum protection of the product inside against oxygen and UV rays. Its cylindrical shape guarantees high restitution rates (up to 98% of the product delivered) and easy filling with basic equipment, the firm says.

The metering pump delivers a constant and precise dose of 0.92ml.

The Elestrin sales pack used by the Irish pharmaceutical firm includes two 38ml Sillage airless metering dispensers for a two-month treatment.

Lablabo, based in Annemasse, says it has Drug Master Files (DMFs) registered with the FDA for all of it products and received ISO 15378 certification last December.

See more

You may also like

Drug Delivery

How are biotech companies using microspheres to go beyond oncology?

Read more
Biotech companies are increasingly using microsphere drug delivery technology to expand advanced therapies beyond traditional cancer treatments. In oncology, microspheres (e.g. drug-eluting beads) have been used to localise chemotherapy and reduce side effects

Trending Articles

  1. Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic blood-brain barrier transporter approaches. The results also suggest strong support for therapeutically relevant clinical effects of semaglutide using MetP Pharma’s DDT
  2. AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
  3. New research suggests repurposed diabetic drug may help prostate cancer A class of medication called SGLT2 inhibitors, traditionally used for diabetes, may help slow prostate cancer progression in men receiving hormone treatment
  4. Astoriom acquires Precision Stability Storage, expanding sample management capabilities The acquisition strengthens Astoriom’s stability storage capabilities to meet increasing demand across North America and offers reliable, compliant and accessible solutions to advance scientific discovery and product development
  5. Biosero launches GoSimple™, a standardised automation-ready workcell GoSimple workcells simplify workflows and enhance lab efficiency with selected Sartorius and BD instruments

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

You may also like

Drug Delivery

How are biotech companies using microspheres to go beyond oncology?

Biotech companies are increasingly using microsphere drug delivery technology to expand advanced therapies beyond traditional cancer treatments. In oncology, microspheres (e.g. drug-eluting beads) have been used to localise chemotherapy and reduce side effects
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Drug Delivery

Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma

The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic blood-brain barrier transporter approaches. The results also suggest strong support for therapeutically relevant clinical effects of semaglutide using MetP Pharma’s DDT
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Pharmaceutical

New research suggests repurposed diabetic drug may help prostate cancer

A class of medication called SGLT2 inhibitors, traditionally used for diabetes, may help slow prostate cancer progression in men receiving hormone treatment
Drug Delivery

Indonesia looks to oral GLP-1s as it battles rising obesity

Novo Nordisk's oral GLP-1 therapy for chronic weight management could help the country deliver injectable-comparable weight loss alongside cardiovascular risk-reduction benefits for its expanding population
Subscribe now